Hikma Pharmaceuticals, a generic drug maker from Jordan, said on Tuesday it had priced its initial public offering (IPO) of shares at 290 pence each, near the middle of its indicative range of 265 to 330 pence.

Hikma, which makes and sells a range of branded and non-branded generic pharmaceuticals, said the offer price would give the company a market value of around £483 million ($858.8 million) and would raise gross proceeds of £148.8 million.

Hikma Chief Executive and Chairman Samih Darwazah said the IPO had attracted strong interest from a broad range of investors in the UK, Europe, the United States and the Middle East.

Unconditional dealings in Hikma shares are likely to begin on the main market of the London Stock Exchange tomorrow.